Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (89)	8/15/2001 3:17:00 PM
From: Jibacoa	Read Replies (1) \| Respond to of 544

Yes, it was a good up-gap on TEVA as expected.<g> siliconinvestor.com ENMD is moving up from its lows after the FDA granted "orphan drug" status to Endostatin & Panzem. Endostatin and Panzem are currently in early stages of human testing. "The FDA based its decision on early data that showed the drugs do not produce dose-limiting toxic side effects", EntreMed said. siliconinvestor.com It is still way down from its March 2000 H of 101.25 <g> siliconinvestor.com Bernard